Semax

Semax is a synthetic peptide drug developed in Russia. Key points:

• Composed of the ACTH(4-7) fragment (Met-Glu-His-Phe) with an added Pro-Gly-Pro at the C-terminus
• Also known as MEHFPGP, I5FAL2585H, Pro-Gly-Pro-ACTH(4-7), ACTH(4–7)PGP
• Molecular formula: C39H55N11O11
• Developed by the Institute of Molecular Genetics of the Russian Academy of Sciences
• Approved for medical use in Russia for various neurological conditions

Semax works through several mechanisms:

• 1 Stimulates neurotrophic factors, particularly Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF)
• 2 Impacts serotonin, dopamine, and enkephalin signaling
• 3 Modulates the expression of genes related to the immune system and vascular function
• 4 May act as an antagonist or partial agonist of melanocortin receptors (MC4 and MC5)
• 5 Inhibits enzymes involved in the degradation of enkephalins

• Improves attention and short-term memory
• Enhances learning and mental clarity

• Protects against pressure-induced nerve damage in glaucoma
• Shows protective effects against various neurotoxins
• Potential benefits in stroke and ischemic conditions

• May have antidepressant-like and anxiolytic-like effects
• Enhances stress resilience

• Affects the expression of cytokine genes
• May have antiviral properties

• Typical dose: 300-600 mcg per day
• Often divided into 1-3 doses

• Higher dose: 600-1200 mcg per day
• Usually divided into 1-2 doses

• Highest dose: 1000-3000 mcg per day
• Often administered 1-2 times daily

Semax is typically available as a pre-mixed nasal spray or solution. For research purposes:

• 1 If using lyophilized powder, reconstitute with bacteriostatic water
• 2 Use sterile equipment for mixing and administration
• 3 Calculate dosage based on concentration (e.g., 0.1% or 1% solution)

• Tilt head back slightly
• Insert dropper or spray nozzle into nostril
• Administer prescribed dose
• Allow solution to absorb through nasal mucosa

For research purposes, subcutaneous injection may also be used.

Limited data on combinations. Potential synergistic effects with:

• Nootropics (e.g., racetams)
• Other peptides (e.g., Selank)

Always research potential interactions before combining substances.

Semax is available through specialized pharmacies in Russia. For research purposes, it may be obtained from reputable peptide suppliers. Always ensure third-party testing and proper documentation.

Generally considered to have a favorable safety profile:

• No notable side effects reported in clinical trials
• Safely administered in doses up to 12mg/daily for 10 consecutive days
• Long-term safety data is limited

Potential side effects may include:

• Headache
• Nasal irritation
• Slight anxiety at higher doses

• Approved for medical use in Russia
• Not approved by FDA or EMA for human use
• Legal status varies by country
• Often available as a research chemical, not for human consumption

• Store in a cool, dry place away from direct light
• Refrigerate after opening
• Use within 30 days after opening
• Do not freeze
• Keep out of reach of children

Effects may be noticeable within 5-30 minutes of administration, with peak effects occurring within 2-4 hours.

While some studies have used Semax for up to 30 days, long-term safety data is limited. Consult a healthcare professional for extended use.

Some studies suggest improvements in attention and memory, but more research is needed to confirm these effects in healthy populations.

Yes, ipamorelin can be used by women. Some studies suggest it may be particularly beneficial for postmenopausal women in terms of body composition and bone density. However, it should not be used during pregnancy or breastfeeding.

Semax shows promise as a neuroprotective and cognitive-enhancing peptide with a favorable safety profile. The typical dosage range of 300-3000 mcg per day, depending on the application, appears effective for most research purposes. However, its use should be approached cautiously due to limited long-term safety data and varying legal status worldwide. As with any experimental compound, thorough research and professional consultation are essential before use.

• 1 Gusev EI, et al. (2005). Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 105(2), 35-40.
• 2 Dolotov OV, et al. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54-60.
• 3 Medvedeva EV, et al. (2014). The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics, 15(1), 228.
• 4 Manchenko DM, et al. (2010). The effects of semax and its Pro-Gly-Pro fragment on calcium homeostasis of neurons and their survival under conditions of glutamate toxicity. Russian Journal of Bioorganic Chemistry, 36(2), 268-274.
• 5 Asmarin IP, et al. (1997). A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study). Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova, 47(2), 420-430.